Gemcitabine, ifosfamide and vinorelbine in advanced non-small cell lung cancer: A phase II study

Anticancer Research

Volumn 22, Issue 2 B, 2002, Pages 1321-1328

  Recchia, Francesco ^a   Lombardo, Marco ^a   De Filippis, Sandro ^a   Rosselli, Michele ^a   Rea, Silvio ^a  

^a NONE   (Italy)

Author keywords

Advanced non small cell lung cancer; Chemotherapy; Gemcitabine; Ifosfamide; Vinorelbine

Indexed keywords

GEMCITABINE; IFOSFAMIDE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; VINBLASTINE;

EID: 0036324660     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Cancer Statistics, 1998
2. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
3. Non small cell lung cancer
4. The expanding role of cisplatin in the treatment of non-small cell lung cancer
5. Single agent versus combination chemotherapy in patients with advanced non small cell lung carcinoma: A meta-analysis of response, toxicity and survival
6. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer
7. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluorodeoxycytidine)
8. Gemcitabine: A pharmacologic and clinical overview
9. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer. A phase II study
10. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
11. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer:A phase II study
12. Ifosfamide in non-small-cell lung cancer: A review
13. Chemotherapy of non-small-cell lung cancer according to disease extent: A meta-analysis of the literature
14. Ifosfamide in experimental tumor systems
15. European experience with ifosfamide in non-small-cell lung cancer
16. Ifosfamide
17. A phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small cell lung cancer
18. Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research
19. Experimental antitumor activity of Navelbine
20. Phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer
21. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
22. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model
23. Carboplatin, ifosfamide and vinorelbine in the treatment of advanced non small cell lung cancer. A phase II study
24. Ifosfamide, Vinorelbine and Gemcitabine in advanced non-small cell lung cancer. A phase I study
25. Reporting results of cancer treatment
26. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
27. Optimal two-stage design for phase II clinical trials
28. Nonparametric estimation from incomplete observations
29. Combined cisplatin and gemcitabine for non-small cell lung cancer: Influence of scheduling on toxicity and drug delivery
30. Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer
31. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study
32. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: A phase II study of three different doses
33. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer
34. The fine points of end points: Phase II trials in lung cancer
35. Combined gemcitabine, ifosfamide and vinorelbine (GIN): Activity and safety of a non-platinum-based regimen in advanced non-small-cell lung cancer (NSCLC)
36. First-line treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbine
37. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
38. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
39. A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer